Sanofi Consumer Sales Slow As Pandemic-Driven Surge Ends, But OTC Xyzal Line Still Shines

Sanofi says slower sales after consumers stockpiled cold and cough products in Q1 combined with OTC Zantac removal US and Canada drove 8% drop in consumer health care sales in Q2 to $1.18bn. Xyzal allergy brand had stellar results in the US and worldwide sales grew 76.9%.

Xyzal , Sanofi Q
The Xyzal OTC allergy line was a bright spot in Sanofi's second-quarter consumer health results.

Widespread dips in sales, particularly in Europe, after consumers stopped pandemic-driven stockpiling of OTC drugs and nutritional products, and the removal of OTC allergy Zantac in the US took big chunks out of Sanofi’s consumer health care sales in its latest quarter.

More from Earnings

More from Business